Metastasis, the deadliest aspect of cancer, is notoriously resistant to treatment. The Ludwig Center at the University of Chicago is searching for new ways to take advantage of cutting-edge technologies to identify, characterize and target disseminated tumor cells, with the goal of eventually developing successful treatment or prevention strategies for metastasis.


The Chicago Center explores various aspects of cancer metastasis—the cause of some 90% of cancer-related deaths—for clues to its effective treatment. One of our current research areas focuses on the development of novel selective steroid receptor modulators and degraders to target steroid receptors, both individually and in different combinations, to more effectively prevent, treat and inhibit the metastatic spread of hormone-dependent breast and prostate cancers. Another key element of our Center’s mission is the investigation of oligometastatic disease, an intermediate state of cancer progression characterized by metastases that are limited in number and pace of formation. These investigations include studies of how microRNAs influence metastatic behavior, the immune activating and suppressing effects of radiotherapy and the harnessing of that knowledge to improve cancer therapy. By understanding the biological mechanisms that govern both the metastatic state and the host immune response to radiation, we hope to increase the number of metastatic cancer patients amenable to cure.

The Ludwig Center is housed within the University of Chicago Medical Center.


Principal Investigators



More News


Postdoctoral scholar at the Ludwig Center at Chicago
Deadline: September 15, 2021
See More

Postdoctoral scholar at the Ludwig Center at Chicago

The University of Chicago’s Ludwig Center for Metastasis Research in the Department of Radiation and Cellular Oncology is seeking Postdoctoral Scholars to join a diverse and vibrant lab with a long history of breakthrough translational research. Openings currently exist in research teams seeking to better understand and reduce the process of tumor metastasis and improve the anti-tumor action of cancer therapies. Several key collaborations are driving our lab’s current focus: through our ongoing collaboration with Dr. Yang-Xin Fu we continue to investigate core pathways and mechanisms underlying immune responses in the context of radiotherapy and immunotherapy; Dr. Chuan He has been working with us recently to elucidate the effects of modification of m6A methylation on the anti-tumor action of radiotherapy and immunotherapy; and we are partnering with Dr. Wenbin Lin to develop immuno-nanomedicine approaches that can be employed with radiotherapy. Recent publications from these collaborative investigations include Yang et al. J Exp Med 2021, Hou et al. Sci Transl Med 2021, Zheng et al. Cancer Res 2020, Shi et al. J Exp Med 2020, Ni et al. Sci Adv 2020, Arina et al. Nat Commun 2019, Chan et al. Biomaterials 2019, Han et al. Nature 2019, Hou et al. Immunity 2018, Liang et al. Nat Commun 2017; Xu et al. Immunity 2017; Deng et al. J Clin Invest 2014, and Deng et al. Immunity 2014. Additional opportunities to consult and/or participate in the composition and execution of translational research grant applications and design and implementation of clinical trials related to immunology and radiotherapy are also available. Qualified applicants must possess a doctorate degree. Ideal candidates would possess a strong background in radiation biology or immunology, with experience in tumor biology and/or tumor immunology, standard immunology techniques/assays, adoptive Tcell therapy, molecular biology, animal models of human cancer, and bioinformatic analysis. Successful Postdoctoral Scholars in our lab independently drive and conduct their research, with guidance and input from the rest of the group, and therefore they must work well in a team environment. The level of the position and compensation are dependent upon qualifications and experience. We are looking for candidates from a diversity of backgrounds; indeed, over the past five years, Postdoctoral Scholars and Fellows in the Weichselbaum Lab have hailed from seven countries. Interested candidates should submit curriculum vitae, bibliography, a statement of research interests, and contact information for at least three references to Dr. R. Weichselbaum, Dept. of Radiation and Cellular Oncology, 5758 S. Maryland Ave, MC9006, Chicago, IL 60637 USA, or via email to:

The University of Chicago is an Affirmative Action/Equal Opportunity/Disabled/Veterans Employer and does not discriminate on the basis of race, color, religion, sex, sexual orientation, gender identity, national or ethnic origin, age, status as an individual with a disability, protected veteran status, genetic information, or other protected classes under the law (including Title IX of the Education Amendments of 1972). For additional information please see the University’s Notice of Nondiscrimination at Job seekers in need of a reasonable accommodation to complete the application process should call 773-702-0287 or email with their request.

See Full Job Posting    

   Back to Locations

Ludwig Center at the University of Chicago
5758 South Maryland Avenue MC 9006
Chicago, Illinois, U.S. 60637

T 773 702 0817
F 773 834 7233


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?